194 related articles for article (PubMed ID: 19187195)
1. Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII.
Bajwa N; Enriquez MM; Gorina E; Lemm G
Haemophilia; 2009 Mar; 15(2):597-600. PubMed ID: 19187195
[No Abstract] [Full Text] [Related]
2. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A.
Young JH; Liu HC; Hsueh EJ; Huang ML; Peng CT; Chen RL; Maas-Enriquez M; Achilles K
Haemophilia; 2009 Jul; 15(4):968-70. PubMed ID: 19473407
[No Abstract] [Full Text] [Related]
3. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
[TBL] [Abstract][Full Text] [Related]
4. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
[TBL] [Abstract][Full Text] [Related]
5. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
Meijer K; Rauchensteiner S; Santagostino E; Platokouki H; Schutgens RE; Brunn M; Tueckmantel C; Valeri F; Schinco PC
Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A.
Steele MR; Nagel K; Chan AK
Haemophilia; 2014 Jan; 20(1):e100-1. PubMed ID: 24251412
[No Abstract] [Full Text] [Related]
7. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
Singleton E; Smith J; Kavanagh M; Nolan B; White B
Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
[TBL] [Abstract][Full Text] [Related]
8. Factor VIII inhibitor and severity of hemophilia.
Schoppmann A; Waytes AT
Thromb Haemost; 1996 Aug; 76(2):280-1. PubMed ID: 8865549
[No Abstract] [Full Text] [Related]
9. A case report of a premature infant with haemophilia A and factor VIII inhibitor.
Cartledge P; Deakin K; McKecknie L; Richards M
Haemophilia; 2011 Jul; 17(4):711-2. PubMed ID: 21371187
[No Abstract] [Full Text] [Related]
10. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
Gaerisch F; Stein P
Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
[TBL] [Abstract][Full Text] [Related]
11. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII.
Oldenburg J; Ivaskevicius V; Schröder J; Müller CR; Ganguly A
Thromb Haemost; 2006 May; 95(5):903-5. PubMed ID: 16676088
[No Abstract] [Full Text] [Related]
12. Factor VIII assays in haemophilia a patients treated with ReFacto.
Sukhu K; Harrison P; Keeling D
Br J Haematol; 2003 Apr; 121(2):379-80. PubMed ID: 12694265
[No Abstract] [Full Text] [Related]
13. The use of porcine factor VIII in France.
Negrier C
Semin Hematol; 1994 Apr; 31(2 Suppl 4):29-32. PubMed ID: 7939770
[No Abstract] [Full Text] [Related]
14. Use of factor VIII replacement during open heart surgery in a patient with haemophilia A.
Stine KC; Becton DL
Haemophilia; 2006 Jul; 12(4):435-6. PubMed ID: 16834747
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII products in haemophilia A: one size fits all?
Mannucci PM; Garagiola I
Thromb Haemost; 2015 May; 113(5):911-4. PubMed ID: 25854290
[No Abstract] [Full Text] [Related]
16. [in vivo reappearance of injected cryoprecopitate (factor VIII concentrates) in patients with hemophilia A].
Kuble M; Wegner H; Cron D
Z Gesamte Inn Med; 1973 Oct; 28(20):608-14. PubMed ID: 4767194
[No Abstract] [Full Text] [Related]
17. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A.
Scharrer I; Brackmann HH; Sultan Y; Abshire T; Gazengel C; Ragni M; Gorina E; Vosburgh E; Kellermann E
Haemophilia; 2000 Nov; 6(6):614-8. PubMed ID: 11122384
[TBL] [Abstract][Full Text] [Related]
18. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A.
Martinowitz U; Lalezari S; Luboshitz J; Lubetsky A; Spira J
Haemophilia; 2008 Sep; 14(5):1122-4. PubMed ID: 18564190
[No Abstract] [Full Text] [Related]
19. Cardiac surgery in a patient with haemophilia A.
Eren A; Friedl R; Hannekum A; Gulbins H
Thorac Cardiovasc Surg; 2006 Apr; 54(3):212-4. PubMed ID: 16639687
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two pharmacokinetic techniques for individualizing factor VIII dosage in haemophilia patients.
Morfini M; Grasela TH; Longo G; Matucci M; Messori A; Vannini S; Rossi-Ferrini P
Haematologica; 1985; 70(5):454-6. PubMed ID: 3937784
[No Abstract] [Full Text] [Related]
[Next] [New Search]
